[Amherst, MA] Meet with...Johnson & Johnson Innovation
[Amherst, MA] Meet with...Johnson & Johnson Innovation
University of Massachusetts at Amherst, Institute for Applied Life Sciences , Life Science Laboratory Building, 6th Floor , Amherst , MA 01003
October 12, 2017 from 12:30 PM to 15:00 PM (EST)
$10 - $35
Johnson & Johnson Innovation is coming to UMass Amherst!
On October 12, representatives from the Johnson & Johnson Innovation, Boston will be at UMass Amherst’s Institute for Applied Life Sciences to provide an overview of Johnson & Johnson Innovation goals and mission, highlighting how we interact with the entrepreneurial community through our Innovation Center, JLABS, JJDC, JBD and other initiatives.
We will describe Johnson & Johnson Innovation regional centers that host a diverse team of science and transaction experts whose goal is to find high potential early-stage innovation and, if on strategy and a fit for Johnson & Johnson, create customized deal structures to help accelerate the science to the patient. At Johnson & Johnson Innovation, we recognize that a good idea can come from anywhere, and we work with partners at all stages of research and development to nurture the innovation ecosystem and propel the best ideas into solutions for patients.
During the program, UMass Amherst leadership and special guests will make a special announcement regarding the Commonwealth’s ongoing commitment to innovation in life sciences.
Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation. See below for information about applying for a one-on-one meeting, as well as information about a separate afternoon event that will be taking place in the same space.
Areas of interest include:
- Baby care
- Compromised skin
- Feminine personal care
- Oral care
- Vision care
- Infectious Diseases & Vaccines
- Cardiovascular & Metabolism
10:30 AM | Registration Opens and Networking
11:00 AM | Special Announcement
11:15 AM | Presentation and Q&A
12:30 PM | Networking Lunch
1:00-4:00 PM | One-on-one Meetings*
1:00-4:00 PM | UMass Core Facilities Biotech Reception**
*Companies or individuals must have applied for a one-on-one meeting ahead of time and be approved. In order to apply for a one-on-one meeting, please email a 1-page executive summary to Narayan Sampath ([email protected]). The application period ends on October 9.
**Please be advised that directly following lunch, UMass IALS will be hosting a Core Facilities Showcase throughout the afternoon, in the same space. This separate afternoon event will discuss the benefits to academic and industry users of these UMass facilities. To register for that event, click here.
University of Massachusetts at Amherst
Institute for Applied Life Sciences
Life Science Laboratory Building, 6th Floor
240 Thatcher Road
Amherst, MA 01003
Ibraheem Badejo | Senior Director, New Ventures, Johnson & Johnson Innovation read bio»
Nicola La Monica | Senior Director, Infectious Disease and Vaccines Scientific Innovation, Janssen R&D read bio»
Bob Radinsky | Vice President, Oncology Scientific Innovation, Janssen R&D read bio»
Peter Stebbins | Transactions Lead, Medical Devices, Johnson & Johnson Innovation read bio»
Presentation & Lunch
FREE | General Public
FREE | Onsite
Includes presentation, Q&A, and lunch. All attendees must register, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on October 10 (or sold out).
FREE | Application
FREE | Accepted Companies
Companies or individuals must have applied for a one-on-one meeting ahead of time. In order to apply for a one-on-one meeting, please email a 1-page executive summary to Narayan Sampath ([email protected]). Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved. The application period ends on October 9.
Participating Representatives' Biographies:
Ibraheem Badejo, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.
Connect with Ibraheem:
Nicola La Monica | Senior Director, Infectious Disease and Vaccines Scientific Innovation, Janssen R&D
Nicola is Senior Director of Infectious Diseases and Vaccines Scientific Innovation at Johnson & Johnson Innovation, Boston. From 2009 to 2012, Nicola was at Idera Pharmaceuticals, where he was Vice President of biology. From 1991 to 2009, he was the Director of Antiviral Research at the Istituto di Ricerche di Biologia Molecolare (IRBM), Rome, Italy, a research site of Merck Research Laboratories. Prior to that, he held the positions of Director of Oncology and Director of Cancer Immunology and Genomics. During his career, Nicola has led drug discovery efforts for the treatment of Hepatitis C virus infections and oncology, as well as development programs for cancer immunotherapy. Nicola earned his BA degree in Biology from the University of Rochester in 1982. His graduate studies were completed at Columbia University, where he earned a PhD in Microbiology in 1988.
Connect with Nicola:
Robert Radinsky, Ph.D. | Vice President, Oncology Scientific Innovation, Janssen R&D
Robert Radinsky, Ph.D. is Vice President, Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in Johnson & Johnson Innovation, Boston. In this role, he is responsible for identifying and fostering innovation in the region that supports the Oncology Therapeutic Area strategies. Prior to this role, he led Discovery Research, Oncology, for Janssen. Robert has had a very successful oncology research career in both academics and industry. Prior to joining Janssen, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug for the treatment of colorectal carcinoma. Before joining the industry 14 years ago, Robert was on the faculty at The University of Texas MD Anderson Cancer Center in Houston, first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology, and eventually becoming a tenured Associate Professor in the Department of Cancer Biology. He continued as an Adjunct Professor at the MD Anderson Cancer Center after joining the industry. Robert has published more than 130 peer-reviewed articles, holds multiple patents, and is a present/past member of numerous societies, including the American Association for Cancer Research, Board of Directors for the Metastasis Research Society, the American Association for the Advancement of Science, the Scientific Advisory Board and the Aspen Cancer Conference. He is an Editorial Member and/or ad hoc reviewer for more than 20 scientific journals and has served on review panels for a number of granting agencies, including the National Institutes of Health/National Cancer Institute, the Department of Defense Prostate and Breast Cancer Research Programs, and the Veterans Administration Merit Review Board. Robert earned his doctorate in Molecular Biology and Microbiology from Case Western Reserve University School of Medicine in Cleveland, Ohio.
Connect with Bob:
Peter Stebbins | Transactions Lead, Medical Devices, Johnson & Johnson Innovation
In this role, he provides deal leadership in partnering with early stage companies across the medical device sectors. Peter has been with J&J since a business school internship in 1990. He joined the JJIC in November 2016. His previous position was Vice President of Strategy for DePuy Synthes Orthopedics and Business Development for Codman Neuro. Prior to that, Peter held a series of VP positions in Marketing, Strategic Marketing and Business Development for Mitek Sports Medicine and Codman Neuro. He helped reposition Mitek from purely shoulder anchors to arthroscopy enabling solutions and to earlier intervention, exemplified by Orthovisc and Monovisc HA injections for OA. At Codman Neuro, he helped redefine their business by divesting the Instruments business unit and emphasizing neurovascular stroke intervention, exemplified by Micrus and Pulsar. Before his stints in Ortho and Neuro, Peter spent the first half of his career in the Ethicon Surgery businesses, starting in Operations before going into Field Sales and into Marketing, including working in Scotland as Director of European Marketing for Ethicon. Peter studied Chemical Engineering at Princeton on an ROTC scholarship before serving with US Army Forces in West Germany and attending Harvard Business School.